Date: 2012-10-10
Type of information: Collaboration agreement
Compound: drug discovery incubator Inception 3
Company: Roche (Switzerland) Versant Ventures (USA) Inception Sciences (USA)
Therapeutic area: Otorhinolaryngology
Type agreement: collaboration
Action mechanism:
Disease: sensorineural hearing loss
Details: Roche has entered into an exclusive partnership with Versant Ventures and Inception Sciences to create a drug discovery incubator, Inception 3, for the treatment of sensorineural hearing loss. The collaboration will focus on creating novel drug therapies that target inner ear hair cell protection and regeneration in the cochlea. Under the terms of the agreement, Inception 3 will incorporate an innovative technology platform from Stanford University coupled with excellence in drug discovery from the ex-Amira Pharmaceuticals team at Inception Sciences, under the leadership of Peppi Prasit. Versant will provide equity financing to the company and Roche will fund the research based on a series of milestones. Roche retains an exclusive option to acquire Inception 3 upon a first lead compound reaching the filing stage of an investigational new drug (IND) application.
Financial terms:
Latest news:
